Literature DB >> 11230375

Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.

H Peng1, O A Carretero, L Raij, F Yang, A Kapke, N E Rhaleb.   

Abstract

N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) inhibits not only hematopoietic cell proliferation but also fibroblast proliferation and collagen synthesis in vitro. Ac-SDKP also prevents collagen deposition and cell proliferation in the left ventricle (LV) in rats with renovascular hypertension (renin dependent). However, it is not clear whether Ac-SDKP has similar effects in a model of renin-independent hypertension (aldosterone-salt). Using a hypertensive rat model of cardiac and renal fibrosis created by chronic elevation of circulating aldosterone (ALDO) levels, we examined the effect of Ac-SDKP on blood pressure, cardiac and renal fibrosis and hypertrophy, and proliferating cell nuclear antigen (PCNA) expression in the LV and left kidney. Uninephrectomized rats were divided into 4 groups: (1) controls that received tap water, (2) rats that received ALDO (0.75 microgram/h SC) and 1% NaCl/0.2% KCl in drinking water (ALDO-salt), (3) rats that received ALDO-salt plus Ac-SDKP 400 microgram. kg(-1). day(-1) SC, and (4) rats that received ALDO-salt plus Ac-SDKP 800 microgram. kg(-1). d(-1) SC. After 6 weeks of treatment, the ALDO-salt group was found to have significantly increased blood pressure with decreased body weight and plasma renin concentration (P<0.05), LV and renal hypertrophy as well as renal injury, significantly increased collagen content in both ventricles and kidney as well as increased collagen volume fraction in the LV (P<0.0001), and significantly increased interstitial and perivascular PCNA-positive cells in the LV and kidney (P<0.0001). Ac-SDKP at 800 microgram. kg(-1). d(-1) markedly prevented cardiac and renal fibrosis (P<0.005) without affecting blood pressure or organ hypertrophy. It also suppressed PCNA expression in the LV and kidney in a dose-dependent manner. We concluded that Ac-SDKP prevents increased collagen deposition and cell proliferation in the heart and kidney in ALDO-salt hypertensive rats. Because ACE inhibitors increase plasma and tissue Ac-SDKP and decrease cardiac and renal fibrosis, we speculate that Ac-SDKP may participate in the antifibrotic effect of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230375      PMCID: PMC6824419          DOI: 10.1161/01.hyp.37.2.794

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

1.  In vivo effect of the tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro, on the G1-S transition of rat hepatocytes.

Authors:  M N Lombard; D Sotty; J Wdzieczak-Bakala; M Lenfant
Journal:  Cell Tissue Kinet       Date:  1990-03

2.  In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.

Authors:  C Junot; J Menard; M F Gonzales; A Michaud; P Corvol; E Ezan
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

3.  Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats.

Authors:  Y Sun; J Zhang; J Q Zhang; F J Ramires
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

4.  Remodeling of the rat right and left ventricles in experimental hypertension.

Authors:  C G Brilla; R Pick; L B Tan; J S Janicki; K T Weber
Journal:  Circ Res       Date:  1990-12       Impact factor: 17.367

5.  Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats.

Authors:  S Kim; K Ohta; A Hamaguchi; T Omura; T Yukimura; K Miura; Y Inada; T Wada; Y Ishimura; F Chatani
Journal:  Hypertension       Date:  1994-08       Impact factor: 10.190

6.  Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors.

Authors:  D Bonnet; F M Lemoine; S Pontvert-Delucq; C Baillou; A Najman; M Guigon
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

Review 7.  The pathophysiology of obstructive nephropathy: the role of vasoactive compounds in the hemodynamic and structural abnormalities of the obstructed kidney.

Authors:  S Klahr; M L Pukerson
Journal:  Am J Kidney Dis       Date:  1994-02       Impact factor: 8.860

8.  Plasma kinin concentration in deoxycorticosterone-salt hypertension.

Authors:  M Nakagawa; A Nasjletti
Journal:  Hypertension       Date:  1988-05       Impact factor: 10.190

9.  Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  M Azizi; A Rousseau; E Ezan; T T Guyene; S Michelet; J M Grognet; M Lenfant; P Corvol; J Ménard
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.

Authors:  C G Brilla; L S Matsubara; K T Weber
Journal:  Am J Cardiol       Date:  1993-01-21       Impact factor: 2.778

View more
  44 in total

Review 1.  Protein NMR in biomedical research.

Authors:  W Jahnke; H Widmer
Journal:  Cell Mol Life Sci       Date:  2004-02-26       Impact factor: 9.261

2.  Intrapericardial procedures for cardiac regeneration by stem cells: need for minimal invasive access (AttachLifter) to the normal pericardial cavity.

Authors:  H Rupp; T P Rupp; P Alter; N Jung; S Pankuweit; B Maisch
Journal:  Herz       Date:  2010-10       Impact factor: 1.443

3.  N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Martin D'Ambrosio; Yanlu Zhang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

4.  Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  Yanlu Zhang; Zheng Gang Zhang; Michael Chopp; Yuling Meng; Li Zhang; Asim Mahmood; Ye Xiong
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

5.  N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1β-mediated matrix metalloproteinase activation in cardiac fibroblasts.

Authors:  Nour-Eddine Rhaleb; Saraswati Pokharel; Umesh C Sharma; Hongmei Peng; Edward Peterson; Pamela Harding; Xiao-Ping Yang; Oscar A Carretero
Journal:  Pflugers Arch       Date:  2013-05-08       Impact factor: 3.657

Review 6.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

7.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

8.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.

Authors:  Saman Rasoul; Oscar A Carretero; Hongmei Peng; Maria A Cavasin; Jialong Zhuo; Alicia Sanchez-Mendoza; David R Brigstock; Nour-Eddine Rhaleb
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

9.  Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.

Authors:  Li Zhang; Michael Chopp; Hua Teng; Guangliang Ding; Quan Jiang; Xiao Ping Yang; Nour Eddine Rhaleb; Zheng Gang Zhang
Journal:  Stroke       Date:  2014-02-18       Impact factor: 7.914

10.  Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; Tang-Dong Liao; Edward L Peterson; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2007-02-05       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.